Literature DB >> 31833348

Combination of prednisolone and cyclosporin A as third-line therapy for refractory Kawasaki disease: a case study.

Masamune Higashigawa1, Tomomi Nakamura2, Tomoki Hattori2, Ayako Yoshino2, Mitsue Ito2, Ryoji Ichimi2.   

Abstract

BACKGROUND: The selection of drugs as third-line therapy for patients with Kawasaki disease (KD) who are resistant to second-line therapy remains controversial.
METHODS: We reviewed the medical records of 354 patients (216 males/137 females) with KD who were treated in our department from July 2003 to January 2016. The age range was 1 month to 10 years, and the median age was 2 years and 1 month. A combination of 2 g/kg intravenous immunoglobulin (IVIG) plus 30 mg/kg of aspirin was used as first-line therapy. Patients who were refractory to the first-line therapy were administered 2 mg/kg of prednisolone (PSL) in combination with IVIG. Five patients who were refractory to the second-line therapy were treated with cyclosporine A (CsA) combined with PSL as the thirdline therapy.
RESULTS: All five patients immediately responded to the third-line therapy. One of the five patients showed a transient dilatation of the coronary artery that regressed to its normal size by the 60th day of illness.
CONCLUSIONS: We suggest that the combination of CsA and steroids might be a promising therapeutic strategy for refractory KD.

Entities:  

Year:  2019        PMID: 31833348     DOI: 10.23736/S0026-4946.19.05567-1

Source DB:  PubMed          Journal:  Minerva Pediatr        ISSN: 0026-4946            Impact factor:   1.312


  1 in total

1.  Combined Single Nucleotide Variants of ORAI1 and BLK in a Child with Refractory Kawasaki Disease.

Authors:  Saki Kanda; Yoshimitsu Fujii; Shin-Ichiro Hori; Taichi Ohmachi; Ken Yoshimura; Koichiro Higasa; Kazunari Kaneko
Journal:  Children (Basel)       Date:  2021-05-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.